BSE:507747

Stock Analysis Report

Executive Summary

TTK Healthcare Limited engages in the pharmaceutical, consumer product, medical device, protective device, and food businesses primarily in India.

Snowflake

Fundamentals

Flawless balance sheet average dividend payer.


Similar Companies

Share Price & News

How has TTK Healthcare's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

2.1%

507747

3.0%

IN Pharmaceuticals

3.1%

IN Market


1 Year Return

-48.6%

507747

-18.9%

IN Pharmaceuticals

3.7%

IN Market

Return vs Industry: 507747 underperformed the Indian Pharmaceuticals industry which returned -18.9% over the past year.

Return vs Market: 507747 underperformed the Indian Market which returned 3.7% over the past year.


Shareholder returns

507747IndustryMarket
7 Day2.1%3.0%3.1%
30 Day-6.9%-4.2%5.7%
90 Day-15.2%-2.5%1.4%
1 Year-48.1%-48.6%-18.2%-18.9%5.9%3.7%
3 Year-54.8%-55.8%-26.1%-27.6%22.3%16.0%
5 Year-39.2%-41.1%-11.7%-14.3%42.5%28.9%

Price Volatility Vs. Market

How volatile is TTK Healthcare's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is TTK Healthcare undervalued compared to its fair value and its price relative to the market?

31.46x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Undervalued: 507747 (₹448.4) is trading above our estimate of fair value (₹142.83)

Significantly Undervalued: 507747 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 507747 is poor value based on its PE Ratio (31.5x) compared to the Pharmaceuticals industry average (15.8x).

PE vs Market: 507747 is poor value based on its PE Ratio (31.5x) compared to the Indian market (13.2x).


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate 507747's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 507747 is overvalued based on its PB Ratio (2.5x) compared to the IN Pharmaceuticals industry average (1.5x).


Next Steps

Future Growth

How is TTK Healthcare forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

12.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 507747's forecast earnings growth (12.3% per year) is above the savings rate (7.6%).

Earnings vs Market: 507747's earnings (12.3% per year) are forecast to grow slower than the Indian market (18.2% per year).

High Growth Earnings: 507747's earnings are forecast to grow, but not significantly.

Revenue vs Market: Insufficient data to determine if 507747's revenue is forecast to grow faster than the Indian market.

High Growth Revenue: Insufficient data to determine if 507747's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if 507747's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has TTK Healthcare performed over the past 5 years?

11.1%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: 507747's earnings have grown by 11.1% per year over the past 5 years.

Accelerating Growth: 507747's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 507747 had negative earnings growth (-48.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (14.4%).


Return on Equity

High ROE: 507747's Return on Equity (8%) is considered low.


Return on Assets

ROA vs Industry: 507747's Return on Assets is below or equal to the Pharmaceuticals industry average last year.


Return on Capital Employed

ROCE Improving: 507747's Return on Capital Employed has declined over the past 3 years.


Next Steps

Financial Health

How is TTK Healthcare's financial position?


Financial Position Analysis

Short Term Liabilities: 507747's short term assets (₹2.7B) exceeds its short term liabilities (₹1.6B)

Long Term Liabilities: 507747's short term assets (2.7B) exceeds its long term liabilities (73.1M)


Debt to Equity History and Analysis

Debt Level: 507747's debt to equity ratio (11.1%) is considered satisfactory

Reducing Debt: 507747's debt to equity ratio has reduced from 28.4% to 11.1% over the past 5 years.

Debt Coverage: 507747's debt is well covered by operating cash flow (62.1%).

Interest Coverage: 507747 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet

Inventory Level: 507747 has a high level of physical assets or inventory.

Debt Coverage by Assets: 507747's debt is covered by short term assets (assets are 9.744940x debt).


Next Steps

Dividend

What is TTK Healthcare's current dividend yield, its reliability and sustainability?

1.12%

Current Dividend Yield


Dividend Yield vs Market

company1.1%marketbottom25%0.6%markettop25%2.5%industryaverage0.9%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: 507747's dividend (1.12%) is higher than the bottom 25% of dividend payers in the Indian market (0.6%).

High Dividend: 507747's dividend (1.12%) is low compared to the top 25% of dividend payers in the Indian market (2.48%).

Stable Dividend: 507747's dividends per share have been stable in the past 10 years.

Growing Dividend: 507747's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (35.1%), 507747's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

What is the CEO of TTK Healthcare's salary, the management and board of directors tenure and is there insider trading?

5.2yrs

Average board tenure


CEO

T. Raghunathan (67yo)

5.2yrs

Tenure

₹20,662,869

Compensation

Mr. T. T. Raghunathan, B.Com., has been the Chief Executive Officer of TTK Healthcare Limited since August 22, 2014. Mr. Raghunathan has been Managing Director of TTK - LIG Ltd., since February 01, 2013. M ...


CEO Compensation Analysis

Compensation vs. Market: T.'s total compensation ($USD290.63K) is above average for companies of similar size in the Indian market ($USD28.94K).

Compensation vs Earnings: T.'s compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.


Board Age and Tenure

5.2yrs

Average Tenure

65.5yo

Average Age

Experienced Board: 507747's board of directors are considered experienced (5.2 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Sell₹1,368,07704 Dec 18
Sanjeev Rawat
EntityIndividual
Shares1,800
Max Price₹769.05

Ownership Breakdown


Management Team

  • T. Raghunathan (67yo)

    Executive Vice Chairman & CEO

    • Tenure: 5.2yrs
    • Compensation: ₹20.66m
  • B. V. K. Prasad (58yo)

    Senior VP of Finance & CFO

    • Tenure: 5.2yrs
    • Compensation: ₹7.35m
  • S. Kalyanaraman (57yo)

    Wholetime Secretary

    • Tenure: 5.2yrs
    • Compensation: ₹9.73m
  • S. Rao (54yo)

    Senior Vice President of Business Development - Foods

    • Tenure: 0yrs
  • Yogesh Yadav (52yo)

    Vice President of National Sales - CPD

    • Tenure: 0yrs
  • K. Sunil (56yo)

    Senior Vice President of Heart Valve

    • Tenure: 0yrs
  • R. Saranyan (52yo)

    President of Protective Devices Division

    • Tenure: 0yrs
  • P. Venkateswaran (50yo)

    Business Head of Ortho

    • Tenure: 0yrs
  • K. Ramaprasad (49yo)

    Vice President of Supply Chain

    • Tenure: 0yrs
  • Brijj Singh (51yo)

    Vice President - Operations (PDD)

    • Tenure: 0yrs

Board Members

  • Vandana Walvekar (76yo)

    Independent Director

    • Tenure: 5.2yrs
    • Compensation: ₹120.00k
  • K. Shankaran (66yo)

    Non-Executive Director

    • Tenure: 19yrs
    • Compensation: ₹300.00k
  • T. Raghunathan (67yo)

    Executive Vice Chairman & CEO

    • Tenure: 5.2yrs
    • Compensation: ₹20.66m
  • T. Jagannathan (70yo)

    Chairman

    • Tenure: 0yrs
    • Compensation: ₹60.00k
  • Girish Rao (57yo)

    Independent Director

    • Tenure: 5.2yrs
    • Compensation: ₹200.00k
  • R. Tulshan (65yo)

    Non-Executive Non-Independent Director

    • Tenure: 34.9yrs
    • Compensation: ₹200.00k
  • S. Kalyanaraman (57yo)

    Wholetime Secretary

    • Tenure: 5.2yrs
    • Compensation: ₹9.73m
  • S. Balasubramanian

    Independent Director

    • Tenure: 4.6yrs
    • Compensation: ₹160.00k
  • N. Rajan

    Independent Director

    • Tenure: 3.7yrs
    • Compensation: ₹60.00k
  • V. Ranganathan (61yo)

    Additional Director

    • Tenure: 0.3yrs

Company Information

TTK Healthcare Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: TTK Healthcare Limited
  • Ticker: 507747
  • Exchange: BSE
  • Founded: 1958
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₹6.205b
  • Shares outstanding: 14.13m
  • Website: https://www.ttkhealthcare.com

Number of Employees


Location

  • TTK Healthcare Limited
  • 6, Cathedral Road
  • Chennai
  • Tamil Nadu
  • 600086
  • India

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
507747BSE (Mumbai Stock Exchange)YesEquity SharesININRMay 2001
TTKHEALTHNSEI (National Stock Exchange of India)YesEquity SharesININRMay 2001

Biography

TTK Healthcare Limited engages in the pharmaceutical, consumer product, medical device, protective device, and food businesses primarily in India. The company’s Pharmaceuticals segment deals in herbal and  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/18 12:35
End of Day Share Price2019/10/18 00:00
Earnings2019/06/30
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.